Effect of intravenous Dexamethasone on prevention of complications of laryngeal mask airway in inguinal region surgeries

Effect of intravenous Dexamethasone on prevention of complications of laryngeal mask airway (LMA) in inguinal region surgeries

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200730048255N1

Enrollment

140

Registered

2020-09-05

Start date

2020-08-24

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inguinal region surgeries.

Interventions

Intervention 1: Intervention group (70 patients): This group will have general anesthesia with LMA. After establishing the airway, Dexamethasone 8 mg / IV / stat will be injected. Intervention 2: Cont

Eligibility

Sex/Gender

All

Age

15 Years to 50 Years

Inclusion criteria

Inclusion criteria: Patients who are candidate for inguinal region surgery (hernia and unilateral varicocele repair) and undergo general anesthesia using classical LMA is selected.

Exclusion criteria

Exclusion criteria: Dissatisfaction of eligible patients to participate in the study American Society of Anesthesiologists = 3

Design outcomes

Primary

Measure	Time frame
Nausea and vomiting. Timepoint: After extubation, postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Nausea and Vomiting score: score 1: no nausea and vomiting; score 2: nausea; score 3: 1 or 2 times nausea and vomiting; score 4: nausea and vomiting more than 2 times.;Cough. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Sore throat. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Chills. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Chills score: score 0: No chills; score 1: peripheral vasoconstriction and peripheral cyanosis without specific cause but without visible muscle contraction; score 2: visible contraction limited to one muscle group; score 3: visible contraction in more than one muscle group; score 4: Clear muscle activity throughout the body.;Odynophagia. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Dyspnea. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Epigastric pain. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.	—

Measure

Time frame

Nausea and vomiting. Timepoint: After extubation, postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Nausea and Vomiting score: score 1: no nausea and vomiting; score 2: nausea; score 3: 1 or 2 times nausea and vomiting; score 4: nausea and vomiting more than 2 times.;Cough. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Sore throat. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Chills. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Chills score: score 0: No chills; score 1: peripheral vasoconstriction and peripheral cyanosis without specific cause but without visible muscle contraction; score 2: visible contraction limited to one muscle group; score 3: visible contraction in more than one muscle group; score 4: Clear muscle activity throughout the body.;Odynophagia. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Dyspnea. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.;Epigastric pain. Timepoint: Postoperative recovery, 2 and 4 hours after surgery. Method of measurement: Asking the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArezoo Fekrat

Ardabil University of Medical Sciences

arezoo.fekrat@gmail.com+98 45 3371 0774

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026